Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Low adherence to cervical cancer screening guidelines among women survivors after allogeneic hematopoietic cell transplantation: Predictors and practice gaps from a single-center analysis

Prajna Woonnimani, Amanda Bruegl, Haley Burns, Jessica Currier, Kate Bolten, Talia Frost-Belansky, Emily Van Houweling, Jennifer Saultz, Andy Chen, Jessica Leonard, Amrita Desai, Staci Williamson, Laura Newell, Brandon Hayes-Lattin, Gabrielle Meyers, Richard Maziarz, Rachel Cook, Arpita Gandhi

Blood (2025) 146 (Supplement 1): 7784.

https://doi.org/10.1182/blood-2025-7784

Published: 2025

Journal Articles

Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more

Howard Chang, Staci Williamson, Daniel Chandra, Andy Chen, Rachel Cook, Amrita Desai, Arpita Gandhi, Brandon Hayes-Lattin, Curtis Lachowiez, Jessica Leonard, Richard Maziarz, Laura Newell, Jennifer Saultz, Ronan Swords, Elie Traer, Gabrielle Meyers

Blood (2025) 146 (Supplement 1): 4252.

https://doi.org/10.1182/blood-2025-4252

Published: 2025

Journal Articles

Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML

Curtis Lachowiez, Andy Kaempf, Carolyn Lehn, Tara Lundberg Williams, Gabriella Sheldon, Jessica Leonard, Gabrielle Meyers, Arpita Gandhi, Jennifer Saultz, Brandon Hayes-Lattin, Richard Maziarz, Rachel Cook, Ronan Swords, Gordon Mills, Theodore Braun

Blood (2025) 146 (Supplement 1): 1649.

https://doi.org/10.1182/blood-2025-1649

Published: 2025

Journal Articles

Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models

Smith Kungwankiattichai, Sanjog Bastola, Manoj Rai, Amrita Desai, Andy Chen, Craig Okada, Brandon Hayes-Lattin, Stephen Spurgeon, Tanaya Shree, Weerapat Owattanapanich, Staci Williamson, Bashi Ratterree, Rachel Bixler, Chi Phan, Robert Ahrenkiel, Richard Maziarz

Blood (2025) 146 (Supplement 1): 3726.

https://doi.org/10.1182/blood-2025-3726

Published: 2025

Journal Articles

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Blood (2025) 146 (Supplement 1): 928.

https://doi.org/10.1182/blood-2025-928

Published: 2025

Journal Articles

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Veronika Bachanova, Qing Cao, Marie Hu, Supriya Gupta, Miguel-Angel Perales, Olalekan Oluwole, Richard Maziarz, Joseph McGuirk, Andy Chen, Stephen J. Schuster, Gunjan Shah, Anthony Hunter, Jamie Brower, David Porter, Peter Riedell

Blood (2025) 146 (Supplement 1): 400.

https://doi.org/10.1182/blood-2025-400

Published: 2025

Journal Articles

Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

Blood (2025) 146 (Supplement 1): 6085.

https://doi.org/10.1182/blood-2025-6085

Published: 2025

Journal Articles

The impact of first line tyrosine kinase inhibitors (TKI) on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Virginia Tan, Jean Sabile, Amrita Desai, Arpita Gandhi, Jennifer Saultz, Gabrielle Meyers, Laura Newell, Rachel Cook, Elie Traer, Curtis Lachowiez, Ronan Swords, Richard Maziarz, Theodore Braun, Brandon Hayes-Lattin, Jessica Leonard

Blood (2025) 146 (Supplement 1): 3372.

https://doi.org/10.1182/blood-2025-3372

Published: 2025

Journal Articles

Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Results from a Phase 1B study

Blood (2025) 146 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2025-3354

Published: 2025

Journal Articles

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1

Blood (2025) 146 (Supplement 1): 256.

https://doi.org/10.1182/blood-2025-256

Published: 2025

Journal Articles

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Blood (2025) 146 (Supplement 1): 1083.

https://doi.org/10.1182/blood-2025-1083

Published: 2025

Journal Articles

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

Chen Zhang, Xiaowen Sun, Lei Feng, David Porter, Stephen J. Schuster, Olalekan Oluwole, Veronika Bachanova, Supriya Gupta, Joseph McGuirk, Richard Maziarz, Andy Chen, Sairah Ahmed, Peter Riedell, Anthony Hunter, Paolo Strati

Blood (2025) 146 (Supplement 1): 957.

https://doi.org/10.1182/blood-2025-957

Published: 2025

Journal Articles

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML

Blood (2025) 146 (Supplement 1): 7744.

https://doi.org/10.1182/blood-2025-7744

Published: 2025

Journal Articles

Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium

Alexandra Rojek, Alyssa Gibson, Marina Gomez-Llobell, Miguel-Angel Perales, Joseph McGuirk, Stephen Schuster, David Porter, Jamie Brower, Hanan Alharthy, Sairah Ahmed, Richard Maziarz, Veronika Bachanova, Olalekan Oluwole, Anthony Hunter, Peter Riedell

Blood (2025) 146 (Supplement 1): 2707.

https://doi.org/10.1182/blood-2025-2707

Published: 2025

Journal Articles

Pro-Tmune, the Next Generation Graft for Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety and Efficacy Data

Richard Maziarz, MD, John Edwards, MD, James Essell, MD, Cesar Freytes, MD, Chatchada Karanes, MD, Ayman Saad, MD, Dimitrios Tzachanis, MD PhD, Monica Diaz, Amanda Medcalf, Daniel Fremgen, Chris Storgard, MD, Abhinav Deol, MD

Blood (2017) 130 (Supplement 1): 4498.

https://doi.org/10.1182/blood.V130.Suppl_1.4498.4498

Published: 2017

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study

Philippe Armand, MD, PhD, Waleska Perez, MPH, Mei-Jie Zhang, PhD, Haesook Kim, PhD, Thomas R. Klumpp, MD, Paola Dal Cin, PhD, Edmund K Waller, MD, PhD, Mark R. Litzow, MD, Jane L. Liesveld, MD, Hillard M. Lazarus, MD, FACP, Andrew Artz, MD, MS, Vikas Gupta, MD, MRCP, FRCPath, Bipin N. Savani, MD, Philip L. McCarthy, MD, Jean-Yves Cahn, MD, Harry Schouten, Jurgen Finke, MD, Edward D. Ball, MD, Mahmoud Aljurf, MD, Corey Cutler, MD, MPH, FRCPC, Jacob M. Rowe, Joseph H. Antin, MD, Luis M Isola, MD, Paolo Di Bartolomeo, MD, Bruce Camitta, MD, Alan M Miller, MD, PhD, Mitchell S. Cairo, MD, Keith E. Stockerl-Goldstein, MD, Jorge Sierra, MD, Mary Lynn Savoie, MD, FRCPC, Joerg Halter, MD, Patrick J Stiff, MD, Chadi Nabhan, MD, FACP, Ann A. Jakubowski, MD, PhD, Donald Bunjes, MD, Effie W. Petersdorf, MD, Steven M Devine, MD, Richard Maziarz, MD, Martin Bornhauser, MD, Victor A Lewis, MD, David I. Marks, MBBS, PHD, Christopher N Bredeson, MD, MSc, FRCPC, Robert Soiffer, MD, Daniel J. Weisdorf, MD

Blood (2010) 116 (21): 680.

https://doi.org/10.1182/blood.V116.21.680.680

Published: 2010

Journal Articles

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Blood (2010) 116 (21): 3450.

https://doi.org/10.1182/blood.V116.21.3450.3450

Published: 2010

Journal Articles

Impact of Prior Therapy with Imatinib Mesylate on the Outcome of Hematopoietic Cell Transplantation (HCT) for Chronic Myeloiod Leukemia (CML).

Stephanie Lee, MD, Richard Maziarz, MD, Manisha Kukreja, MBBS, MPH, Tao Wang, PhD, Sergio Giralt, MD, Jeffrey Szer, MBBS, Ann Woolfrey, MD, Mukta Arora, MD, MS

Blood (2007) 110 (11): 738.

https://doi.org/10.1182/blood.V110.11.738.738

Published: 2007

Journal Articles

Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL).

Andrew R. Rezvani, MD, Brenda M. Sandmaier, MD, Barry Storer, PhD, Michael Maris, MD, Edward Agura, MD, Richard Maziarz, MD, James C. Wade, MD, Thomas Chauncey, MD, PhD, Stephen J. Forman, MD, Dietger W. Niederwieser, MD, Judith Shizuru, MD, Amelia Langston, MD, Michael Pulsipher, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD

Blood (2006) 108 (11): 3124.

https://doi.org/10.1182/blood.V108.11.3124.3124

Published: 2006

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Low adherence to cervical cancer screening guidelines among women survivors after allogeneic hematopoietic cell transplantation: Predictors and practice gaps from a single-center analysis

Comparison of 80 mg/kg vs. 100 mg/kg post-transplant cyclophosphamide dose with flu/mel and allogeneic transplant: Less is not more

Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML

Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Comparable outcomes in patients aged ≥70 vs. <70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

The impact of first line tyrosine kinase inhibitors (TKI) on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab for the upfront treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), Results from a Phase 1B study

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine–1

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Activity of autologous anti-CD19 chimeric antigen receptor T-cell therapy in CD19-negative large B-cell lymphoma: A cell therapy consortium real world experience

FluMel100 with post-transplant cyclophosphamide: A safe and effective regimen for patients aged ≥75 years with MDS and AML

Impact of bridging therapies prior to CAR T cell therapy for large B-cell lymphoma: Real-world analysis from the cell therapy consortium

Pro-Tmune, the Next Generation Graft for Allogeneic Hematopoietic Cell Transplantation: Phase 1 Safety and Efficacy Data

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Impact of Prior Therapy with Imatinib Mesylate on the Outcome of Hematopoietic Cell Transplantation (HCT) for Chronic Myeloiod Leukemia (CML).

Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only